Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 10, 2006. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline Executive Supplemental Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications.
Material Changes
Changes in interests in Ordinary Share ADRs were reported for four individuals following the re-investment of dividends paid on October 5, 2006. The transactions occurred at a price of $53.95 per share under the Annual Investment Plan feature.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is a regulatory disclosure of specific shareholding changes.
Important Facts for Investors
- Transaction Date: Dividends were reinvested on October 5, 2006, with notification on October 6, 2006.
- Share Price: The reinvestment price was $53.95 per share.
- Directors Involved: Dr. J-P Garnier, Dr. F Calhoun, Dr. D Pulman, and Mr. D Stout.
- Share Increases:
- Dr. J-P Garnier: 297.426 shares
- Dr. F Calhoun: 306.570 shares
- Dr. D Pulman: 16.025 shares
- Mr. D Stout: 244.023 shares